SightfileU.S. market data from official filings

IMMUNOCORE HLDGS PLC (IMCR)

Name: IMMUNOCORE HLDGS PLC (IMCR) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001671927 · EDGAR filings · Updated 2026-05-28

IMMUNOCORE HLDGS PLC (IMCR) has reported institutional ownership of 103.0%, with 142 institutional managers holding positions valued at $1.58B per the latest 13F reporting period.

Institutional ownership

103.0%

Institutional managers

142

Reported 13F value

$1.58B

Insider activity

32 trans.

−$10.4M net selling

Latest updates

2026-05-28 — Insider transaction reported (Form 4)
2026-05-28 — Insider transaction reported (Form 4)
2026-05-28 — Insider transaction reported (Form 4)
2026-05-28 — Insider transaction reported (Form 4)
2026-05-28 — Insider transaction reported (Form 4)
2026-05-28 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, IMMUNOCORE HLDGS PLC has 142 institutional holders and institutional ownership of 103.0%.

Insider activity

Insiders reported 32 transactions (0 buys, 17 sells) across 4 reporting insiders, with a net reported value of −$10.4M.

Related companies

TREVI THERAPEUTICS INC (TRVI) · HEARTFLOW INC (HTFL) · AMYLYX PHARMACEUTICALS INC (AMLX) · MBX BIOSCIENCES INC (MBX) · HARMONY BIOSCIENCES HLDGS IN (HRMY) · ANAPTYSBIO INC (ANAB)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-05-28.